Pluristem Therapeutics Inc. (NasdaqCM: PSTI; TASE: PLTR) is a leading developer of placenta-based cell therapies. The company's patented PLX (PLacental eXpanded) cells drug delivery platform releases a cocktail of therapeutic proteins in response to a variety of local and systemic inflammatory diseases. PLX cells are grown using the company’s proprietary 3D micro-environmental technology and are an off-the-shelf product that requires no tissue matching or immune-suppression treatment prior to administration. PLX-PAD comprehensive clinical development plan has been recognized by both the EMA and FDA, targeting a sub-population of 20-million patients of Peripheral Artery Disease (PAD) market.
The Company recently announced that the compassionate use of its PLX Cells had saved the life of a young Romanian girl suffering from aplastic bone marrow, a condition in which patients have no blood-forming hematopoietic stem cells in their bone marrow. Her doctor, Professor Reuven Or, explained that "With her body rejecting all possible treatment -- and with no other options -- we finally turned to Pluristem's PLX cells, which literally saved her life." Read more.
Below is a video from Reuters about the girl, her condition, and the remarkable reversal of her disease.